1. Pink Sheet
  2. >>Compliance

US FDA Explains How It Will Resume Inspections Suspended By Pandemic

 
• By Bowman Cox

Phased approach will prioritize the safety of FDA and industry employees while striking ‘an appropriate balance between a scaled-back surveillance inspection program and the continuation of providing robust regulatory oversight,’ Commissioner Hahn says in a memo from self-isolation.

3d different tablets and pills on a white background with question marks

The US Food and Drug Administration is developing a plan for resuming surveillance inspections suspended by the COVID-19 pandemic, according to a statement commissioner Stephen Hahn issued 11 May, three days after he self-quarantined due to possible exposure to the virus.

The plan, part of President Trump’s effort to reopen an economy devastated by fear of COVID-19, comes as routine testing and contact tracing is revealing an potential outbreak in the White House that would likely go undetected if it

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Compliance

More from Pink Sheet

Viatris Agrees To $335m Opioid Settlement Ending US State, Local Government Cases

 
• By Dean Rudge

Viatris joined Hikma and Amneal, in signing agreements for cash settlements that resolve allegations its practices fueled the US’ deadly opioid epidemic.

Pharma Predicts Modest Tariff Impact, Depending On What Comes Next

 
• By Jessica Merrill

Drugmakers are not expecting a big financial hit from tariffs for now, but a report commissioned by the industry trade association PhRMA suggests a potentially steep cost for pharma-sector tariffs.

What The EMA Can Teach HTA Bodies About Joint Clinical Assessments

 
• By Francesca Bruce

EU-level joint clinical assessments conducted under the Health Technology Assessment Regulation need to be more flexible when it comes to evidence requirements, according to experts speaking at a gene and cell therapy conference.